Corcept Therapeutics Inc
Closed
SectorHealthcare
109.34 -2.43
Overview
Share price change
24h
Min
108.84
Max
112.91
Income | -130M -32M |
|---|---|
Sales | -37M 165M |
P/E Sector Avg | 260.343 64.641 |
EPS | -0.3 |
Profit margin | -19.26 |
Employees | 730 |
EBITDA | -55M -44M |
Recommendations | Buy |
|---|---|
12 Months Forecast | +8.69% upside |
Next Earnings | 3 lis 2026 |
|---|
Market Cap | 4.8B 9.8B |
|---|---|
Previous open | 111.77 |
Previous close | 109.34 |
Corcept Therapeutics Inc Chart
Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.
Related News
Peer Comparison
Price change
Corcept Therapeutics Inc Forecast
Price Target
By TipRanks
8.69% upside
12 Months Forecast
Average 122.6 USD 8.69%
High 165 USD
Low 50 USD
Based on 5 Wall Street analysts offering 12 month price targets forCorcept Therapeutics Inc - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Corcept Therapeutics Inc
Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.
